Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…
Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and over
On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and over
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of…
Novavax filed in the UK for expanded conditional Marketing Authorization of COVID-19 vaccination booster in adult
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…
Novavax initiated phase 3 trial of its COVID-19 Omicron strain vaccine as a booster
On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…
Novavax participated in Oxford University Com-COV3 booster trial of COVID-19 vaccines in adolescents aged 12 through 15
On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations…
Novavax filed in the EU for expanded conditional Marketing Authorization of COVID-19 vaccine as booster in individuals aged 18 and over
On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency (EMA) to…
Novavax filed for Emergency Use Authorization of COVID-19 vaccine in Taiwan
On May 13, 2022, Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food…
Novavax submitted variations to expand Australian and New Zealand provisional approval of Nuvaxovid COVID-19 vaccine in Great Britain
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
NIH launched clinical trial of Epstein-Barr virus vaccine
On May 6, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had launched…
Novavax’s COVID-19 vaccine Nuvaxovid arrived in Singapore
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
Novavax announced initiation of COVID-19 vaccine booster study in adolescents in phase 3 PREVENT-19 trial
On Apr. 22, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
Initial results from Novavax’ COVID-19-Influenza vaccine trial were first to show feasibility of combination vaccine
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
Novavax announced approval of Nuvaxovid COVID-19 vaccine for primary and booster immunization in Japan
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
Novavax and Serum Institute of India received EUA for COVID-19 vaccine in Thailand
On Apr. 8, 2022, Novavax announced and Serum Institute of India (SII), the world’s largest vaccine manufacturer by…
Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescents
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…
Novavax announced extended durability of protection against infection and disease in UK COVID-19 vaccine phase 3 clinical Trial
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
Novavax announced shipments of COVID-19 vaccine to European Union member states
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
Novavax and Serum Institute of India announced first EUA of COVID-19 vaccine in adolescents =12 to <18 in India
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
Health Canada authorized Novavax COVID-19 vaccine
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
Singapore Health Sciences Authority issued interim authorization for Novavax COVID-19 vaccine
On Feb. 14, 2022, Novavax announced that the Singapore Health Sciences Authority (HSA) had issued interim authorization for…
Novavax files for conditional Marketing Authorization of COVID-19 vaccine in Switzerland
On Feb. 14, 2022, Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional…
Novavax announced positive results of COVID-19 vaccine in pediatric population of PREVENT-19 phase 3 clinical trial
On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…
UK MHRA granted Conditional Marketing Authorization for Novavax COVID-19 vaccine in Great Britain
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
New Zealand’s Medsafe granted provisional approval for Novavax’ COVID-19 vaccine
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
Novavax and Israel announced advance purchase agreement for supply of COVID-19 vaccine
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
Australia Therapeutic Goods Administration granted provisional registration for Novavax COVID-19 vaccine
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…